Summer Seminar Session 4

We will be discussing AD plasma biomarkers in participants with Down syndrome. Many of our discussions in the past few weeks have centered around how comorbidities and enhanced risk may affect the relationship between biomarker and disease. This week, we will take a closer look at a clinical population that has a genetically determined high risk of AD and amyloid pathology.  

To skim: https://pmc.ncbi.nlm.nih.gov/articles/PMC5239773/ 

• Montoliu-Gaya L, Alcolea D, Ashton N et al: Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study.

For more information regarding this seminar series, please contact jul291@pitt.edu.